Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Dermata Therapeutics, Inc. (DRMA) had Stock-Based Compensation of $0.09M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-2.97M |
|
-- |
|
-- |
|
$3.01M |
|
$-3.01M |
|
$0.05M |
|
$-2.97M |
|
$-2.97M |
|
$-2.97M |
|
$-2.97M |
|
$-2.97M |
|
$-2.97M |
|
$-3.01M |
|
$-3.01M |
|
4.02M |
|
4.02M |
|
$-0.74 |
|
$-0.74 |
|
| Balance Sheet Financials | |
$5.16M |
|
$0.13M |
|
$0.16M |
|
$5.32M |
|
$1.83M |
|
-- |
|
-- |
|
$1.83M |
|
$3.49M |
|
$3.49M |
|
$3.49M |
|
4.02M |
|
| Cash Flow Statement Financials | |
$-4.90M |
|
$-0.11M |
|
$1.90M |
|
$7.52M |
|
$4.41M |
|
$-3.11M |
|
|
Stock-Based Compensation |
$0.09M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.81 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-85.07% |
|
-85.07% |
|
-55.76% |
|
-85.07% |
|
$0.87 |
|
$-1.25 |
|
$-1.22 |
|